Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

Q4 2015

IXJ Guru Trades in Q4 2015

Ken Fisher 92,228 sh (+380.03%)
» More
Q1 2016

IXJ Guru Trades in Q1 2016

Ken Fisher 12,122 sh (-86.86%)
» More
Q2 2016

IXJ Guru Trades in Q2 2016

Ken Fisher 17,624 sh (+45.39%)
» More
Q3 2016

IXJ Guru Trades in Q3 2016

Ken Fisher 17,922 sh (+1.69%)
» More

Ratios

vs
industry
vs
history
P/E(ttm) 21.48
IXJ's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 21.48 )
Ranked among companies with meaningful P/E(ttm) only.
IXJ' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.55
Current: 21.48
0
24.55
PE(NRI) 21.48
IXJ's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 21.48 )
Ranked among companies with meaningful PE(NRI) only.
IXJ' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.55
Current: 21.48
0
24.55
P/B 3.32
IXJ's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 3.32 )
Ranked among companies with meaningful P/B only.
IXJ' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.78
Current: 3.32
0
3.78

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.99
IXJ's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 1.99 )
Ranked among companies with meaningful Dividend Yield only.
IXJ' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.03
Current: 1.99
0
2.03
Yield on cost (5-Year) 1.99
IXJ's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 1.99 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IXJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.03
Current: 1.99
0
2.03

More Statistics

Short Percentage of Float0.00%
52-Week Range $90.50 - 105.75
Shares Outstanding (Mil)14,250,000.00
» More Articles for IXJ

Headlines

Articles On GuruFocus.com
Low-Priced Retail Stocks Gurus Shopped for Ahead of Holiday Season Dec 02 2016 
Barrick Repurchases $595 Million of Corporate Loan Dec 02 2016 
23 Questions With Bakul Lalla Dec 02 2016 
Qualcomm: Balance Sheet, Dividend Yield Make It Attractive Dec 02 2016 
Apple: A Dividend Achiever in the Making Dec 02 2016 
Neiman Marcus Debenture Bonds Yielding 8% Dec 02 2016 
Competitor Performance Is Eating Nike’s Lunch Dec 02 2016 
Smith & Wesson Reports Strong Quarter, but Stock Suffers Post Election Dec 02 2016 
6 Things That May Surprise You About Building Wealth Dec 02 2016 
Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals Dec 02 2016 

More From Other Websites
Inside Merck’s Business Segment-Wise Performance Dec 01 2016
Allergan’s Valuation Compared to Its Peers Nov 29 2016
Inside Eli Lilly’s Neuroscience Franchise Nov 23 2016
What Can We Expect of Pfizer’s 3Q16 Earnings? Oct 28 2016
Novartis’s 3Q16 Estimates: How Has Sandoz Performed? Oct 24 2016
Word on the Street about Merck’s Animal Health Segment Oct 24 2016
How Did Johnson & Johnson’s Pharmaceutical Segment Do in 3Q16? Oct 21 2016
Eli Lilly and Co.’s 3Q16 Estimates: Neuroscience Franchise Oct 19 2016
Johnson & Johnson’s Pharmaceuticals Segment: 3Q16 Estimates Oct 14 2016
AstraZeneca Is Taking Steps to Improve Its Position in Oncology Sep 19 2016
Roche Sees Soaring Revenue from Its Bladder Cancer Treatment Sep 16 2016
What Investors Can Glean from GlaxoSmithKline’s Revenue Trend Sep 09 2016
Is Johnson & Johnson’s Valuation High Compared to Its Peers? Aug 30 2016
AstraZeneca’s Recent Product Developments Aug 25 2016
AstraZeneca and Its Oncology Segment’s Growth in 2Q16 Aug 25 2016
How Crestor Weakened AstraZeneca’s CVMD Segment in 2Q16 Aug 24 2016
Remicade Is Driving Down Merck’s Immunology Franchise Aug 16 2016
How Are Eli Lilly’s New Products Performing? Aug 04 2016
Revenues from Eli Lilly’s Cymbalta Are Depressed Internationally Aug 03 2016
What to Expect from Pfizer’s 2Q16 Earnings Aug 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK